Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Phase 3

Completed

Conditions: Follicular Lymphoma

Interventions: Drug: Rituximab-CHOP
Drug: Rituximab
Drug: Rituximab-CVP
Drug: Lenalidomide
Drug: Rituximab-Bendamustine

First Posted Date: 2011-11-22

Last Posted Date: 2025-05-14

Lead Sponsor: Celgene

Target Recruit Count: 1030

Registration Number: NCT01476787

Locations: 🇺🇸
Local Institution - 54103, Chandler, Arizona, United States
🇺🇸
Local Institution - 51803, Fullerton, California, United States
🇺🇸
Local Institution - 52003, Los Angeles, California, United States

and more 33 locations

A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pomalidomide
Drug: Placebo

First Posted Date: 2011-11-18

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 33

Registration Number: NCT01474330

Locations: 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States

A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus

Phase 2

Terminated

Conditions: Discoid Lupus

Interventions: Drug: CC-930
Drug: Placebo

First Posted Date: 2011-11-08

Last Posted Date: 2019-11-19

Lead Sponsor: Celgene

Target Recruit Count: 5

Registration Number: NCT01466725

Locations: 🇺🇸
Dermatology and Research, Dallas, Texas, United States
🇺🇸
Advanced Pharma, CR, LLC, Miami, Florida, United States
🇺🇸
University of Miami - Department of Dermatology, Miami, Florida, United States

and more 16 locations

A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)

Phase 1

Completed

Conditions: Lymphoma, T-cell, Peripheral

Interventions: Drug: Romidepsin

First Posted Date: 2011-10-20

Last Posted Date: 2019-02-11

Lead Sponsor: Celgene

Target Recruit Count: 51

Registration Number: NCT01456039

Locations: 🇯🇵
Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan
🇯🇵
Sapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan
🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan

and more 14 locations

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma
Lymphoma, Large B-Cell, Diffuse
Primary Central Nervous System Lymphoma
Glioblastoma
Pleiotropic Pathway Modifier
Lymphoma

Interventions: Drug: CC-122

First Posted Date: 2011-08-23

Last Posted Date: 2023-12-12

Lead Sponsor: Celgene

Target Recruit Count: 271

Registration Number: NCT01421524

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey University, New Brunswick, New Jersey, United States
🇺🇸
City of Hope Cancer Center, Duarte, California, United States
🇺🇸
Texas Oncology, PA - Dallas 75246, Dallas, Texas, United States

and more 36 locations

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Acute Myelogenous Leukemia

Interventions: Drug: Azacitidine
Other: Best Supportive Care (BSC)
Drug: Lenalidomide

First Posted Date: 2011-05-24

Last Posted Date: 2019-06-25

Lead Sponsor: Celgene

Target Recruit Count: 88

Registration Number: NCT01358734

Locations: 🇺🇸
(240) Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
(160) The Western Pennsylvania Hospital- Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
(200) Coastal Integrative Cancer Care, San Luis Obispo, California, United States

and more 27 locations

A Rollover Study for Patients Who Participated in Other Romidepsin Protocols

Phase 2

Completed

Conditions: Lymphoma
Cancer

Interventions: Drug: Romidepsin

First Posted Date: 2011-05-16

Last Posted Date: 2019-11-25

Lead Sponsor: Celgene

Target Recruit Count: 19

Registration Number: NCT01353664

Locations: 🇬🇧
Sarah Cannon Research UK, London, United Kingdom
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

Phase 1

Completed

Conditions: Glioblastoma Multiforme
Squamous Cell Carcinoma of Head and Neck
Prostate Cancer
Ewing's Osteosarcoma
Neoplasm Metastasis
Chronic Lymphocytic Leukemia

Interventions: Drug: CC-115

First Posted Date: 2011-05-13

Last Posted Date: 2021-10-05

Lead Sponsor: Celgene

Target Recruit Count: 118

Registration Number: NCT01353625

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇩🇪
Universitatsklinikum Wurzburg, Würzburg, Germany
🇺🇸
UCLA, Los Angeles, California, United States

and more 14 locations

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Waldenstrom Macroglobulinemia
B Cell Non-Hodgkin's Lymphoma

Interventions: Drug: AVL-292

First Posted Date: 2011-05-11

Last Posted Date: 2019-11-08

Lead Sponsor: Celgene

Target Recruit Count: 113

Registration Number: NCT01351935

Locations: 🇺🇸
University of Arizona SPORE, Tucson, Arizona, United States
🇺🇸
Clearview Cancer Institute Oncology Specialties, P.C, Huntsville, Alabama, United States
🇺🇸
University of California San Diego, La Jolla, California, United States

and more 10 locations

MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry

Completed

Conditions: Myelodysplastic Syndrome

First Posted Date: 2011-05-05

Last Posted Date: 2019-11-18

Lead Sponsor: Celgene

Target Recruit Count: 149

Registration Number: NCT01347944

Locations: 🇮🇹
Dipartimento Onco - Ematologico Azienda Ospedaliera SS Antonio, Biagio e Cesare Arrigo, Alessandria, Italy
🇮🇹
Ematologia Azienda Ospedaliera Universitaria Policlinico di Bari, Bari, Italy
🇮🇹
Ematologia A.O. Ospedale Riuniti di Bergamo, Bergamo, Italy

and more 42 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy